US20100082093A1 - Medical Devices - Google Patents
Medical Devices Download PDFInfo
- Publication number
- US20100082093A1 US20100082093A1 US12/631,430 US63143009A US2010082093A1 US 20100082093 A1 US20100082093 A1 US 20100082093A1 US 63143009 A US63143009 A US 63143009A US 2010082093 A1 US2010082093 A1 US 2010082093A1
- Authority
- US
- United States
- Prior art keywords
- polymer
- wire
- stent
- metal
- expandable stent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 229920000642 polymer Polymers 0.000 claims description 111
- 229910052751 metal Inorganic materials 0.000 claims description 105
- 239000002184 metal Substances 0.000 claims description 101
- 229920001903 high density polyethylene Polymers 0.000 claims description 16
- 239000004700 high-density polyethylene Substances 0.000 claims description 14
- -1 polyethylene Polymers 0.000 claims description 12
- 229920002988 biodegradable polymer Polymers 0.000 claims description 10
- 239000004621 biodegradable polymer Substances 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 10
- 229920003023 plastic Polymers 0.000 claims description 10
- 239000004033 plastic Substances 0.000 claims description 10
- 239000004698 Polyethylene Substances 0.000 claims description 8
- 229920000573 polyethylene Polymers 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 5
- 238000000034 method Methods 0.000 abstract description 15
- 239000000463 material Substances 0.000 description 24
- 238000002595 magnetic resonance imaging Methods 0.000 description 22
- 238000001125 extrusion Methods 0.000 description 8
- 239000000835 fiber Substances 0.000 description 8
- 239000012781 shape memory material Substances 0.000 description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
- 239000001301 oxygen Substances 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 230000008859 change Effects 0.000 description 5
- 229940124597 therapeutic agent Drugs 0.000 description 5
- 238000012800 visualization Methods 0.000 description 5
- 229910001069 Ti alloy Inorganic materials 0.000 description 4
- 208000007474 aortic aneurysm Diseases 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 239000013013 elastic material Substances 0.000 description 3
- 229960002897 heparin Drugs 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Substances [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 3
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 3
- 239000004810 polytetrafluoroethylene Substances 0.000 description 3
- 201000008982 Thoracic Aortic Aneurysm Diseases 0.000 description 2
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 2
- 208000002223 abdominal aortic aneurysm Diseases 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 238000005056 compaction Methods 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 208000003457 familial thoracic 1 aortic aneurysm Diseases 0.000 description 2
- 238000002594 fluoroscopy Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000000155 melt Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 229910001000 nickel titanium Inorganic materials 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 239000010936 titanium Substances 0.000 description 2
- 229910052719 titanium Inorganic materials 0.000 description 2
- UHKPXKGJFOKCGG-UHFFFAOYSA-N 2-methylprop-1-ene;styrene Chemical compound CC(C)=C.C=CC1=CC=CC=C1.C=CC1=CC=CC=C1 UHKPXKGJFOKCGG-UHFFFAOYSA-N 0.000 description 1
- 229910000838 Al alloy Inorganic materials 0.000 description 1
- 206010002329 Aneurysm Diseases 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 229910000599 Cr alloy Inorganic materials 0.000 description 1
- 229910017535 Cu-Al-Ni Inorganic materials 0.000 description 1
- 229910017773 Cu-Zn-Al Inorganic materials 0.000 description 1
- 229910017767 Cu—Al Inorganic materials 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 238000012307 MRI technique Methods 0.000 description 1
- 229920000339 Marlex Polymers 0.000 description 1
- 229910018643 Mn—Si Inorganic materials 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 239000004696 Poly ether ether ketone Substances 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004642 Polyimide Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229910045601 alloy Inorganic materials 0.000 description 1
- 239000000956 alloy Substances 0.000 description 1
- JRBRVDCKNXZZGH-UHFFFAOYSA-N alumane;copper Chemical compound [AlH3].[Cu] JRBRVDCKNXZZGH-UHFFFAOYSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000013590 bulk material Substances 0.000 description 1
- 238000002288 cocrystallisation Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 229920001940 conductive polymer Polymers 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- LKFHUFAEFBRVQX-UHFFFAOYSA-N decanedioic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.OC(=O)CCCCCCCCC(O)=O LKFHUFAEFBRVQX-UHFFFAOYSA-N 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000005672 electromagnetic field Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000007769 metal material Substances 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- HLXZNVUGXRDIFK-UHFFFAOYSA-N nickel titanium Chemical compound [Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ti].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni].[Ni] HLXZNVUGXRDIFK-UHFFFAOYSA-N 0.000 description 1
- 229910052758 niobium Inorganic materials 0.000 description 1
- 239000010955 niobium Substances 0.000 description 1
- GUCVJGMIXFAOAE-UHFFFAOYSA-N niobium atom Chemical compound [Nb] GUCVJGMIXFAOAE-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000009832 plasma treatment Methods 0.000 description 1
- 239000006223 plastic coating Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000867 polyelectrolyte Polymers 0.000 description 1
- 229920002530 polyetherether ketone Polymers 0.000 description 1
- 239000005020 polyethylene terephthalate Substances 0.000 description 1
- 229920000139 polyethylene terephthalate Polymers 0.000 description 1
- 229920000223 polyglycerol Polymers 0.000 description 1
- 229920001721 polyimide Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 229910052715 tantalum Inorganic materials 0.000 description 1
- GUVRBAGPIYLISA-UHFFFAOYSA-N tantalum atom Chemical compound [Ta] GUVRBAGPIYLISA-UHFFFAOYSA-N 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 229920000785 ultra high molecular weight polyethylene Polymers 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
- A61F2/91—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/88—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure the wire-like elements formed as helical or spiral coils
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
- A61F2/91—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
- A61F2/915—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2002/825—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents having longitudinal struts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
- A61F2/91—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
- A61F2/915—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other
- A61F2002/91533—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other characterised by the phase between adjacent bands
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
- A61F2/86—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure
- A61F2/90—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure
- A61F2/91—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes
- A61F2/915—Stents in a form characterised by the wire-like elements; Stents in the form characterised by a net-like or mesh-like structure characterised by a net-like or mesh-like structure made from perforated sheet material or tubes, e.g. perforated by laser cuts or etched holes with bands having a meander structure, adjacent bands being connected to each other
- A61F2002/9155—Adjacent bands being connected to each other
Definitions
- the invention relates to medical devices, such as stents and stent-grafts.
- the body includes various passageways such as arteries, other blood vessels, and other body lumens. These passageways sometimes become occluded or weakened. For example, the passageways can be occluded by a tumor, restricted by plaque, or weakened by an aneurysm. When this occurs, the passageway can be reopened or reinforced, or even replaced, with a medical endoprosthesis.
- An endoprosthesis is typically a tubular member that is placed in a lumen in the body. Examples of endoprostheses include stents and covered stents, sometimes called “stent-grafts”.
- An endoprosthesis can be delivered inside the body by a catheter that supports the endoprosthesis in a compacted or reduced-size form as the endoprosthesis is transported to a desired site. Upon reaching the site, the endoprosthesis is expanded, for example, so that it can contact the walls of the lumen.
- the endoprosthesis When the endoprosthesis is advanced through the body, its progress can be monitored, e.g., tracked, so that the endoprosthesis can be delivered properly to a target site. After the endoprosthesis is delivered to the target site, the endoprosthesis can be monitored to determine whether it has been placed properly and/or is functioning properly.
- MRI magnetic resonance imaging
- MRI is a non-invasive technique that uses a magnetic field and radio waves to image the body.
- the patient is exposed to a magnetic field, which interacts with certain atoms, e.g., hydrogen atoms, in the patient's body.
- Incident radio waves are then directed at the patient.
- the incident radio waves interact with atoms in the patient's body, and produce characteristic return radio waves.
- the return radio waves are detected by a scanner and processed by a computer to generate an image of the body.
- a device positioned within a patient's body is visible by MRI when the device has a sufficient contrast to noise ratio under MRI.
- a sufficient contrast to noise ratio e.g., greater than about 3 may allow a user to define an edge of a device.
- the invention relates to medical devices.
- the invention features an expandable stent including a polymer wire extending spirally in a first direction about a longitudinal axis of the stent and a metal wire extending spirally in a second direction about the longitudinal axis, wherein the second direction is counter to the first direction.
- Embodiments may include one or more of the following features.
- the polymer wire forms a first angle with the longitudinal axis and the metal wires forms a second angle with the longitudinal axis, wherein the first angle is equal to the second angle.
- the first angle can be different than the second angle.
- the first angle can be less than 35 degrees.
- the second angle can between about 35 degrees and about 90 degrees. In certain embodiments the second angle can be between about 60 degrees and about 85 degrees.
- the metal wire does not form a closed loop within the expandable stent.
- the metal wire can be visible on a magnetic resonance image.
- the metal wire can include a shape memory material, such as for example, a titanium alloy.
- the metal wire can have an oval cross-sectional area.
- the stent can include a plurality of metal wires spirally extending along the second direction.
- the stent can include a plurality of polymer wires spirally extending along the first direction.
- the stent can also include a wire including a shape memory material spirally extending along the first direction.
- the polymer wire can be substantially parallel to the longitudinal axis.
- the polymer wire can include polyethylene, such as a high density polyethylene.
- the polymer wire can have a modulus of elasticity between about 10 GPa and about 80 GPa.
- the polymer wire can have a tensile strength of about 1.2 GPa.
- the polymer wire can be treated with a plasma, such as a cold oxygen plasma.
- the polymer wire can be coated with a plastic.
- the stent can further include a bioabsorable material including a drug on a surface of the stent.
- the bioabsorable material can be on an outer surface of the stent.
- the bioabsorable material can be on an inner surface of the stent.
- the stent can be self expandable.
- the invention features an expandable stent including a polymer wire extending substantially parallel to a longitudinal axis of the stent and a metal wire extending substantially perpendicular to the longitudinal axis, wherein the metal wire contacts the polymer wire.
- Embodiments may include one or more of the following features.
- the metal wire can have a sinusoidal shape.
- the metal wire can be formed into a C shape.
- the metal wire can be visible on a magnetic resonance image.
- the metal wire can be formed into a ring.
- the stent can include a plurality of metal wires extending substantially perpendicular to the longitudinal axis.
- the plurality of metal wires can include a first metal wire including a first metal and a second metal wire including a second metal, wherein the first metal differs from the second metal.
- the polymer wire can include polyethylene, such as for example, a high density polyethylene.
- the polymer wire can include a biodegradable polymer.
- the polymer wire can further include a drug within the biodegradable polymer.
- the polymer wire is treated with a plasma, such as for example, a cold oxygen plasma. At least a portion of the polymer wire can be coated with a plastic.
- the stent can include a plurality of polymer wires, for example four polymer wires, six polymer wires, 8 polymer wires, or more, extending parallel to the longitudinal axis.
- the plurality of wires can include an inner wire positioned on an inner surface of the stent and an outer wire positioned on an outer surface of the stent.
- the inner wire can be fused to the outer wire.
- the polymer wire can include an aperture and the metal wire is positioned within the aperture.
- the stent can be a balloon expandable stent.
- the invention features an expandable stent including a polymer wire and a metal wire contacting the polymer wire, wherein the polymer wire is arrange such that substantially no plastic deformation of the polymer wire occurs during expansion of the stent and the metal wire is arranged to axially strengthen the expandable stent.
- Embodiments may have one or more of the following features.
- the stent can be self expandable.
- the stent can be balloon expandable.
- the metal wire does not form a closed loop within the stent.
- the metal wire is visible on a magnetic resonance image.
- the metal wire can include titanium, such as, for example a titanium alloy.
- the metal wire can have an oval cross-sectional area.
- the polymer wire can be substantially parallel to a longitudinal axis of the stent.
- the polymer wire can include polyethylene, such as for example, a high density polyethylene.
- the polymer wire can include a biodegradable polymer.
- the polymer wire can further include a drug in the biodegradable polymer.
- the polymer wire can be treated with a plasma. A portion of the polymer wire can be coated with a plastic.
- the invention features an expandable stent including a polymer member extending spirally in a first direction about a longitudinal axis of the expandable stent, and a metal member extending spirally in a second direction about the longitudinal axis, the second direction being counter to the first direction.
- Embodiments may include one or more of the following features.
- the metal member includes a shape memory material.
- the polymer member forms a first angle with the longitudinal axis and the metal member forms a second angle with the longitudinal axis, the first angle being equal the second angle.
- the polymer member forms a first angle with the longitudinal axis and the metal member forms a second angle with the longitudinal axis, the first angle being different than the second angle.
- the polymer member is substantially parallel to the longitudinal axis.
- the metal member does not form a closed loop within the expandable stent.
- the invention features an expandable stent including a polymer member extending substantially parallel to a longitudinal axis of the expandable stent, and a metal member extending substantially perpendicular to the longitudinal axis, the metal member contacting the polymer member.
- Embodiments may include one or more of the following features.
- the metal member has a sinusoidal shape, a C shape, or a ring shape.
- the stent further includes a plurality of metal members extending substantially perpendicular to the longitudinal axis.
- the polymer member includes a biodegradable polymer.
- the stent further includes a plurality polymer members extending substantially parallel to the longitudinal axis.
- the invention features an expandable stent including a polymer member and a metal member contacting the polymer member, wherein the polymer member is arranged such that substantially no plastic deformation of the polymer member occurs during expansion of the expandable stent and the metal member is arranged to axially strengthen the expandable stent.
- the metal member does not form a closed loop within the expandable stent.
- the medical device can include a metal element and a polymer element that together provide relatively good mechanical strength and at the same time do not compromise the MRI visibility of the medical device.
- the mechanical strength of the medical device including metal elements and polymer elements allows for expansion and/or contraction of the device without reducing the device's capability to reinforce a body lumen.
- a medical professional can use MRI techniques to position and monitor the device because the metal elements and the polymer elements are arranged within the device so that the metal elements do not produce artifacts that interfere with MRI visibility.
- a medical device including metal elements and polymer elements can be either self expanded or balloon expanded without losing the device's elastic properties. As a result, the medical device can be repeatedly expanded and contracted. As a further result, the expanded medical device maintains the mechanical strength required to reinforce a body lumen.
- FIG. 1 is an illustration of a stent in a compacted state.
- FIG. 2 is an enlarged view of a portion of the stent of FIG. 1 , at area 2 - 2 .
- FIG. 3 is another enlarged view of a portion of a stent.
- FIG. 4 is an illustration of a stent in a compacted state.
- FIG. 5 is an illustration of a stent in a compacted state.
- FIG. 6 is an illustration of the stent of FIG. 5 in an expanded state.
- FIG. 7 is a perspective view of a stent.
- FIG. 8 is a perspective view of a stent.
- FIG. 9 is a cross-sectional view of the stent of FIG. 1 taken along line 9 - 9 .
- an MRI-compatible stent 10 is formed of a composite structure including a plurality of metal wires 24 and a plurality of electrically non-conductive polymer wires 26 .
- Wires 24 and 26 are braided or woven, e.g., as described in Wallsten, U.S. Pat. No. 4,655,771, and extend between the ends 12 and 14 of the stent to define a lumen 20 .
- metal wires 24 extend spirally in a first direction about the longitudinal axis 22 of stent 10 (e.g., clockwise as viewed from one end down the longitudinal axis), and polymer wires 26 extend spirally in an opposing direction (e.g., counter-clockwise as viewed from the same end) about the longitudinal axis.
- metal wires 24 provide stent 10 with good mechanical properties (e.g., sufficient to maintain a body lumen open), while allowing for visualization of material, such as blood or a stenosis, present in the lumen of the stent during MRI.
- Polymer wires 26 reduce the amount of metal wires used to form stent 10 , thereby increasing the MRI compatibility of the stent, and can enhance the flexibility and strength of the stent.
- metal wires 24 are selected and arranged within stent 10 such that they do not adversely affect visualization during an MRI procedure, while providing the stent with its mechanical properties to function properly (i.e., the stent can be compacted to a reduced size and subsequently expanded to support a lumen). More specifically, metal wires 24 are formed such that an electrical current cannot flow in a closed loop about stent 10 . Without wishing to be bound by theory, it is believed that the presence of an electrical current loop can interfere with MRI and reduce visualization.
- an incident electromagnetic field is applied to a stent.
- the magnetic environment of the stent can be constant or variable, such as when the stent moves within the magnetic field (e.g., from a beating heart) or when the incident magnetic field is varied.
- an induced electromotive force emf
- the induced emf in turn can produce an eddy current that induces a magnetic field that opposes the change in magnetic field.
- the induced magnetic field can interact with the incident magnetic field to reduce (e.g., distort) the visibility of material in the lumen of the stent.
- a similar effect can be caused by a radiofrequency pulse applied during MRI.
- stent 10 By forming stent 10 to include electrically conductive portions (as shown, wires 24 ) that cannot form a closed current loop, the occurrence of an eddy current is reduced (e.g., eliminated). Consequently, the occurrence of an induced magnetic field that can interact with the incident magnetic field is also reduced, and the visibility of material in the lumen of stent 10 during MRI can be enhanced.
- Polymer wires 26 also enhance the performance of stent 10 .
- Polymer wires 26 which are electrically non-conductive, do not interfere with MRI signals. Also, by forming stent 10 partially with polymer wires 26 , the amount of metal wires 24 is reduced, thereby reducing the occurrence of static interference as an effect of the magnetic susceptibility of the metal wires. At the same time, polymer wires 26 can provide stent 10 with strength and flexibility.
- polymer wires 26 are arranged such that they are not substantially plastically deformed during compaction and expansion of stent 10 . Without wishing to be bound by theory, it is believed that as stent 10 is expanded, the majority of change in the stent's width and length, and thus most of the stress, occurs in the radial direction (e.g., perpendicular to longitudinal axis 22 ). By positioning polymer wires 26 to have a component along longitudinal axis 22 , plastic deformation of polymer wires 26 can be reduced because the stress experienced by the polymer wires is proportional to their radial component. In certain embodiments, referring to FIGS.
- polymer wires 26 form an angle of about 45° or less (e.g., ⁇ 45°, 40°, 35°, 30°, 25°, 20°, 15°, 10°, 5°, 0°) with longitudinal axis 22 (e.g., 0° ⁇ 45° and thus can be substantially parallel with the longitudinal axis 22 ).
- metal wires 24 can form an angle of 35° or greater (e.g., ⁇ 35°, 40°, 45°, 50°, 55°, 60°, 65°, 70°, 75°, 80°, 85°, 89°) with the longitudinal axis (e.g., 35° ⁇ 90°, e.g., 60° ⁇ 85°) and thus can be substantially perpendicular to the longitudinal axis 22 ).
- polymer wires 26 experience reduced stress associated with expansion and contraction and are therefore less likely to undergo plastic deformation.
- the stress exerted by a body lumen on an expanded stent is mainly in the radial direction.
- metal wires 24 counteract substantially all of the stress exerted by the lumen, thereby reducing the stress experienced by polymer wires 26 .
- the angles that polymer wires 26 and/or metal wires 24 form can vary along the length of stent 10 .
- polymer wires 26 and/or metal wires 24 can form a first angle; and at the middle portion of the stent, the polymer wires and/or metal wires can form a second angle.
- the transitions of one angle to another angle can occur, for example, gradually over the length of the stent or step-wise, such that the stent has discrete segments of different angles form by the wire(s).
- the angles can be varied to affect the flexibility or rigidity of the stent.
- the end portions of the stent can be relatively flexible to conform well with the contours of a body vessel, while the middle portion can be relatively rigid to support the vessel open.
- one of the polymer wires 26 can be replaced with a metal wire as this design does not lead to closed conductive paths in the stent.
- the stent is self expandable (e.g., metal wires include a shape memory material)
- the self expansion capabilities of the stent can be enhanced because the strength of the stent is increased by including an additional metal wire 24 that extends spirally in the counter-clockwise direction.
- the MRI visibility capabilities can be enhanced by replacing one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8 or more) of the metal wires 24 with polymer wires 26 .
- the number of metal wires that are replaced with polymer wires depends on the size and shape of the stent, and ultimately on the ability of the remaining metal wires to self expand the stent to an expanded state. It is believed that by reducing the total number of metal wires within stent 10 , magnetic susceptibility disturbances generated by the stent in an MRI decrease, while the contrast to noise ratio increases to provide increased MRI visibility.
- polymer wire(s) have a limited (e.g., substantially none) radial component, the polymer wire(s) undergo little plastic deformation during compaction and expansion of the stent.
- metal wire(s) 24 have a large radial component to provide the stent with sufficient mechanical properties to support a body lumen. At least one of the metal wires 24 can have a sinusoidal shape, so as to provide additional surface contact between an expanded stent 10 and a patient's body lumen.
- one or more polymer wires 26 e.g., 1, 2, 3, 4, 5, 6, 7, 8 or more hold the metal wires 24 together.
- a mechanical connection between the polymer wires 26 and the metal wires 24 can be created by inserting the metal wires 26 through holes punched into the polymer wires 26 .
- the mechanical connection can also be created by replacing each polymer wire 26 with two polymer wire strips, one in contact with the outer surface 16 and one in contact with the inner surface 18 , and fusing the polymer wire strips together to encapsulate a portion of each metal wire 26 .
- each metal wire 24 can be formed in a “C” shape ( FIG. 7 ) or in a ring shape ( FIG. 8 ).
- Stents such as stent 10 ′, which include “C” shaped metal wires (i.e., metal wires 24 do not create a continuously conductive circuit in a plane perpendicular to longitudinal axis 22 ) do not interfere with MRI visualization as described above.
- stents 10 ′′ that include ring shaped metal wires, such as the stent shown in FIG. 8 may interfere with MRI visualization, but may be useful when view or monitored using fluoroscopic techniques.
- the rings are formed of a metal (e.g., gold, silver, platinum) visible under fluoroscopy so that stent 10 ′′ can be visualized within a patient's body during delivery and placement.
- stent 10 ′′ includes one or more metal rings formed of a first material and one or more metal rings formed of a second material.
- the metal wires labeled 24 a and 24 f in FIG. 8 can be formed of a metal that is more radio-opaque (creates a greater contrast under fluoroscopy) than the metal forming wires 24 b , 24 c , 24 d and 24 e .
- adjacent rings can be formed of a material having a different radiopacity.
- wires 24 a , 24 c , and 24 e can be formed of a metal having a first radiopacity
- wires 24 b , 24 d , and 24 f can be formed of a material having a second radiopacity
- metal wires can include an elastic material that maintains its shape once plastically deformed.
- elastic materials include titanium, titanium alloys, tantalum, niobium, Co—Cr alloys, and alloys described in U.S. Ser. No. 10/112,391 filed on Mar. 28, 2002.
- metal wires can include a shape memory material that expands and/or contracts as a result of a phase change.
- suitable shape memory materials include titanium alloys, such as for example a nickel titanium alloy (e.g., Nitinol), copper aluminum alloys, such as for example Cu—Zn—Al, Cu—Al—Ni, and Cu—Al, Fe—Mn—Si, Au—Ca, and Ni 50 Mn 30 Ga 20 (Ni 50 Mn 30 Ga 20 wires prepared from DC magnetron sputtered Ni 50 Mn 30 Ga 20 films that have been annealed on a glass plate).
- elastic and shape memory materials are flexible materials (e.g., modulus of elasticity is less than about 90 GPa) that have sufficient mechanical strength (e.g., ultimate tensile strength greater than 1 GPa) to reinforce a body lumen even after plastic deformation and/or a phase change.
- Metal wires can be molded or laser cut from a solid tube of material to have a spiral shape.
- the metal wires can have a cross-sectional area of about 2.5 ⁇ 10 ⁇ 5 cm 2 to about 2.5 ⁇ 10 ⁇ 3 cm 2 .
- the radial expansion force of the stent with respect to the amount of metal material used in stent 10 is increased (e.g., maximized).
- metal wires 24 can have other cross-sectional shapes such as, for example, regularly or irregularly polygonal having three or more (e.g., 4, 5, 6, 7, 8 or more) sides, such as rectangular, square, circular, and triangular. Wires of different cross sections can be used in a stent.
- Polymer wires used in either self expanding or balloon expanding stents include flexible and strong polymers that have suitable material properties to aid in body lumen reinforcement and at the same time also have material properties that do not compromise the MRI compatibility of the stent.
- Some examples of polymers include polyethylene, polyimide, polyamide, polycarbonate, polyetheretherketone, and polyethylene terephthalate.
- polymer wires 26 are formed of a highly oriented polymer material, such as polyethylene (e.g., a high density polyethylene (HDPE) material formed using a solid-state extrusion process).
- the HDPE polymer can have an average molecular weight (M w ) of about 400,000 g/mol, and a molecular weight distribution (i.e., polydispersity) of about 3 to 7, for example, a polydispersity of about 5.
- the polymer can have a high molecular weight tail (e.g., 0-10% content of greater than about 1,000,000) to ensure the formation of extended chain crystals.
- a minimal amount ( ⁇ 0.1%) of low molecular weight (e.g., 4000 g/mol or less) fraction is preferred to prevent the premature onset of relaxation processes in the melt and to ensure force transfer during extrusion of the melt through a die.
- Low molecular weight fractions can be removed by extraction in an appropriate solvent (e.g., hexane) to increase the tensile module of the resulting fiber.
- an appropriate solvent e.g., hexane
- Examples of HDPEs are commercially available from, e.g., BASELL (BASF) Corporation under the trade designation LUPULEN 52ZHI; Chevron Philips Corporation under the trade designation MARLEX TR-751; and Solvay Corporation under the trade designations RIGIDEX HM5420 XPH, AH 5493, and BH 5363.
- a polymer wire can be prepared, for example, by extrusion.
- the cross-section of the polymer wire can be as described above for the metal wire.
- the polymer can be extruded to form relatively stiff fibers having the requisite mechanical properties (e.g., Young's modulus (E) of greater than about 10 GPa and a tensile strength of greater than about 1 GPa).
- HDPE fibers can be prepared by solid-state extrusion of melt crystallized spherulitic polyethylene or by drawing solution crystallized gel films (e.g., performed by DSM (Heerlen, The Netherlands) as a process marketed as the Dyneema® Process).
- DSM Heerlen, The Netherlands
- An alternative process involves melt deformation of HDPE under controlled conditions to obtain highly oriented fibers.
- the process involves chain extension of the high molecular weight fraction of HDPE having a linear macromolecular structure during flow just above the solidification temperature, followed by crystallization (e.g., of a high molecular weight fraction) and by co-crystallization e.g., of a low molecular weight fraction) of the remaining material.
- the polymer can be extruded at a temperature close to the crystallization temperature (e.g., a self-blocking temperature, which can be indicated by an extrusion pressure rise, e.g., upward from about 3500 psi) and at a strain rate of about 1000 s ⁇ 1 to solidify the deformed macromolecules before relaxation occurs.
- crystallization occurs from about T g +30 to about T m ⁇ 10 (e.g., from about 135 to about 160° C.).
- Such processing conditions can create an elongated, interlocking morphology that displays exceptional mechanical properties (e.g., a Young's modulus (E) of between about 10-80 GPa and a tensile strength of about 1.2 GPa).
- E Young's modulus
- the fibrils can make up about 5% of the extruded material and can have a diameter of between about 5-25 nm with an aspect ratio of about 200-600.
- the bulk material can be characterized as a lamellar overgrowth chain direction like in the fibrils.
- the extrusion head can be equipped with a pressure transducer and a thermocouple to control pressure and temperature during extrusion. Additional information regarding HDPEs is described in Bashir, Z., et al., J. Mat. Science, 19 (1984), 3713; and Bashir, Z., et al., J. Mat. Science, 19 (1986), 3993.
- the polymer wires 26 are extruded to have a preformed spiral shape. In other embodiments, the polymer wires 26 are molded at a temperature at or below their melting temperature to form the spiral shape.
- the HDPE fibers can be treated with a cold oxygen plasma to increase the biocompatibility of the fibers.
- a cold oxygen plasma to increase the biocompatibility of the fibers.
- the cold oxygen plasma treatment preferably occurs at a temperature at or below the melting temperature of HDPE.
- An example of a suitable cold oxygen plasma technique with the required low temperature is a downstream microwave plasma technique.
- a coating such as for example a plastic coating (e.g., styrene-isobutylene-styrene and poly glycerol sebacate), on top of the plasma treated surface.
- a plastic coating e.g., styrene-isobutylene-styrene and poly glycerol sebacate
- the polymer wires 26 are formed of a biodegradable polymer material, such as for example, poly (L-lactid acid) that disintegrates over a period of time within the patient's body.
- a biodegradable polymer material such as for example, poly (L-lactid acid) that disintegrates over a period of time within the patient's body.
- the biodegradable polymer material does not disintegrate until at least a portion of the metal wires 24 are affixed to the patient's body lumen by tissue growth.
- the biodegradable polymer can include drugs, such as therapeutic agents or pharmaceutically active compounds that are released upon disintegration of the polymer wires.
- therapeutic agents and pharmaceutically active compounds include anti-thrombogenic agents, antioxidants, anti-inflammatory agents, anesthetic agents, anti-coagulants, and antibiotics.
- Other examples suitable therapeutic agents and pharmaceutically active compounds are described in U.S. Pat. No. 5,674,242, commonly assigned U.S. Ser. No. 09/895,
- stent 10 can include and/or be attached to a biocompatible, non-porous or semi-porous polymer matrix made of polytetrafluoroethylene (PTFE), expanded PTFE, polyethylene, urethane, or polypropylene.
- PTFE polytetrafluoroethylene
- expanded PTFE polyethylene
- urethane polypropylene
- the polymer wires 26 can be coated and/or treated with an anti-coagulant, such as for example heparin, to increase the biocompatibility of stent 10 , 10 ′, and 10 ′′.
- an anti-coagulant such as for example heparin
- Examples of methods of applying heparin to polymer surfaces are described in Labarre, Trends. Biomater. Artif. Organs, 15(1) (2001), 1, and Bae et al., Biomaterials, 20 (1999), 529.
- stents 10 , 10 ′ and 10 ′′ can include a bioabsorable material that includes a therapeutic agent and/or a pharmaceutically active compound disposed within the bioabsorable material.
- a bioabsorable material including therapeutic agents is a polyelectrolyte (LBL) coating including layers of chitosan and heparin.
- LBL polyelectrolyte
- the bioabsorable material can be positioned on outer surface 16 and/or inner surface 18 to treat the patient's body lumen.
- Stents 10 , 10 ′ and 10 ′′ can be of any desired shape and size (e.g., coronary stents, aortic stents, peripheral stents, gastrointestinal stents, urology stents, and neurology stents).
- stents 10 , 10 ′ and 10 ′′ can have a diameter of between, for example, 1 mm to 46 mm.
- a coronary stent can have an expanded diameter of from about 2 mm to about 6 mm.
- a peripheral stent can have an expanded diameter of from about 5 mm to about 24 mm.
- a gastrointestinal and/or urology stent can have an expanded diameter of from about 6 mm to about 30 mm.
- a neurology stent can have an expanded diameter of from about 1 mm to about 12 mm.
- An abdominal aortic aneurysm (AAA) stent and a thoracic aortic aneurysm (TAA) stent can have a diameter from about 20 mm to about 46 mm.
- Stents 10 , 10 ′ and 10 ′′ can be used, e.g., delivered and expanded, using a balloon catheter system.
- Suitable catheter systems are described in, for example, Wang U.S. Pat. No. 5,195,969, and Hamlin U.S. Pat. No. 5,270,086.
- Suitable stent delivery are also exemplified by the Ranger® system, available from Boston Scientific Scimed, Maple Grove, Minn.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- Cardiology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Transplantation (AREA)
- Veterinary Medicine (AREA)
- Vascular Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Media Introduction/Drainage Providing Device (AREA)
- Materials For Medical Uses (AREA)
Abstract
Expandable stents and methods of using expandable stent within a body are described.
Description
- The invention relates to medical devices, such as stents and stent-grafts.
- The body includes various passageways such as arteries, other blood vessels, and other body lumens. These passageways sometimes become occluded or weakened. For example, the passageways can be occluded by a tumor, restricted by plaque, or weakened by an aneurysm. When this occurs, the passageway can be reopened or reinforced, or even replaced, with a medical endoprosthesis. An endoprosthesis is typically a tubular member that is placed in a lumen in the body. Examples of endoprostheses include stents and covered stents, sometimes called “stent-grafts”.
- An endoprosthesis can be delivered inside the body by a catheter that supports the endoprosthesis in a compacted or reduced-size form as the endoprosthesis is transported to a desired site. Upon reaching the site, the endoprosthesis is expanded, for example, so that it can contact the walls of the lumen.
- When the endoprosthesis is advanced through the body, its progress can be monitored, e.g., tracked, so that the endoprosthesis can be delivered properly to a target site. After the endoprosthesis is delivered to the target site, the endoprosthesis can be monitored to determine whether it has been placed properly and/or is functioning properly.
- One method of monitoring a medical device is magnetic resonance imaging (MRI). MRI is a non-invasive technique that uses a magnetic field and radio waves to image the body. In some MRI procedures, the patient is exposed to a magnetic field, which interacts with certain atoms, e.g., hydrogen atoms, in the patient's body. Incident radio waves are then directed at the patient. The incident radio waves interact with atoms in the patient's body, and produce characteristic return radio waves. The return radio waves are detected by a scanner and processed by a computer to generate an image of the body.
- A device positioned within a patient's body is visible by MRI when the device has a sufficient contrast to noise ratio under MRI. For example, a sufficient contrast to noise ratio (e.g., greater than about 3) may allow a user to define an edge of a device.
- The invention relates to medical devices.
- In one aspect, the invention features an expandable stent including a polymer wire extending spirally in a first direction about a longitudinal axis of the stent and a metal wire extending spirally in a second direction about the longitudinal axis, wherein the second direction is counter to the first direction.
- Embodiments may include one or more of the following features. The polymer wire forms a first angle with the longitudinal axis and the metal wires forms a second angle with the longitudinal axis, wherein the first angle is equal to the second angle. The first angle can be different than the second angle. The first angle can be less than 35 degrees. The second angle can between about 35 degrees and about 90 degrees. In certain embodiments the second angle can be between about 60 degrees and about 85 degrees.
- The metal wire does not form a closed loop within the expandable stent. The metal wire can be visible on a magnetic resonance image. The metal wire can include a shape memory material, such as for example, a titanium alloy. The metal wire can have an oval cross-sectional area. The stent can include a plurality of metal wires spirally extending along the second direction.
- The stent can include a plurality of polymer wires spirally extending along the first direction. The stent can also include a wire including a shape memory material spirally extending along the first direction.
- The polymer wire can be substantially parallel to the longitudinal axis. The polymer wire can include polyethylene, such as a high density polyethylene. The polymer wire can have a modulus of elasticity between about 10 GPa and about 80 GPa. The polymer wire can have a tensile strength of about 1.2 GPa. To increase the biocompatibility of the polymer wire, the polymer wire can be treated with a plasma, such as a cold oxygen plasma. The polymer wire can be coated with a plastic.
- The stent can further include a bioabsorable material including a drug on a surface of the stent. The bioabsorable material can be on an outer surface of the stent. The bioabsorable material can be on an inner surface of the stent.
- The stent can be self expandable.
- In another aspect, the invention features an expandable stent including a polymer wire extending substantially parallel to a longitudinal axis of the stent and a metal wire extending substantially perpendicular to the longitudinal axis, wherein the metal wire contacts the polymer wire.
- Embodiments may include one or more of the following features. The metal wire can have a sinusoidal shape. The metal wire can be formed into a C shape. The metal wire can be visible on a magnetic resonance image. The metal wire can be formed into a ring. The stent can include a plurality of metal wires extending substantially perpendicular to the longitudinal axis. The plurality of metal wires can include a first metal wire including a first metal and a second metal wire including a second metal, wherein the first metal differs from the second metal.
- The polymer wire can include polyethylene, such as for example, a high density polyethylene. The polymer wire can include a biodegradable polymer. The polymer wire can further include a drug within the biodegradable polymer. To increase the biocompatibility of the polymer wire, the polymer wire is treated with a plasma, such as for example, a cold oxygen plasma. At least a portion of the polymer wire can be coated with a plastic.
- The stent can include a plurality of polymer wires, for example four polymer wires, six polymer wires, 8 polymer wires, or more, extending parallel to the longitudinal axis. The plurality of wires can include an inner wire positioned on an inner surface of the stent and an outer wire positioned on an outer surface of the stent. The inner wire can be fused to the outer wire. In certain embodiments, the polymer wire can include an aperture and the metal wire is positioned within the aperture.
- The stent can be a balloon expandable stent.
- In another aspect, the invention features an expandable stent including a polymer wire and a metal wire contacting the polymer wire, wherein the polymer wire is arrange such that substantially no plastic deformation of the polymer wire occurs during expansion of the stent and the metal wire is arranged to axially strengthen the expandable stent.
- Embodiments may have one or more of the following features. The stent can be self expandable. The stent can be balloon expandable.
- The metal wire does not form a closed loop within the stent. The metal wire is visible on a magnetic resonance image. The metal wire can include titanium, such as, for example a titanium alloy. The metal wire can have an oval cross-sectional area.
- The polymer wire can be substantially parallel to a longitudinal axis of the stent. The polymer wire can include polyethylene, such as for example, a high density polyethylene. The polymer wire can include a biodegradable polymer. The polymer wire can further include a drug in the biodegradable polymer. The polymer wire can be treated with a plasma. A portion of the polymer wire can be coated with a plastic.
- In another aspect, the invention features an expandable stent including a polymer member extending spirally in a first direction about a longitudinal axis of the expandable stent, and a metal member extending spirally in a second direction about the longitudinal axis, the second direction being counter to the first direction.
- Embodiments may include one or more of the following features. The metal member includes a shape memory material. The polymer member forms a first angle with the longitudinal axis and the metal member forms a second angle with the longitudinal axis, the first angle being equal the second angle. The polymer member forms a first angle with the longitudinal axis and the metal member forms a second angle with the longitudinal axis, the first angle being different than the second angle. The polymer member is substantially parallel to the longitudinal axis. The metal member does not form a closed loop within the expandable stent.
- In another aspect, the invention features an expandable stent including a polymer member extending substantially parallel to a longitudinal axis of the expandable stent, and a metal member extending substantially perpendicular to the longitudinal axis, the metal member contacting the polymer member.
- Embodiments may include one or more of the following features. The metal member has a sinusoidal shape, a C shape, or a ring shape. The stent further includes a plurality of metal members extending substantially perpendicular to the longitudinal axis. The polymer member includes a biodegradable polymer. The stent further includes a plurality polymer members extending substantially parallel to the longitudinal axis.
- In another aspect, the invention features an expandable stent including a polymer member and a metal member contacting the polymer member, wherein the polymer member is arranged such that substantially no plastic deformation of the polymer member occurs during expansion of the expandable stent and the metal member is arranged to axially strengthen the expandable stent. In embodiments, the metal member does not form a closed loop within the expandable stent.
- Embodiments may have one or more of the following advantages. The medical device can include a metal element and a polymer element that together provide relatively good mechanical strength and at the same time do not compromise the MRI visibility of the medical device. For example, the mechanical strength of the medical device including metal elements and polymer elements allows for expansion and/or contraction of the device without reducing the device's capability to reinforce a body lumen. Moreover, a medical professional can use MRI techniques to position and monitor the device because the metal elements and the polymer elements are arranged within the device so that the metal elements do not produce artifacts that interfere with MRI visibility. A medical device including metal elements and polymer elements can be either self expanded or balloon expanded without losing the device's elastic properties. As a result, the medical device can be repeatedly expanded and contracted. As a further result, the expanded medical device maintains the mechanical strength required to reinforce a body lumen.
- Other aspects, features and advantages of the invention will be apparent from the description of the preferred embodiments and from the claims.
-
FIG. 1 is an illustration of a stent in a compacted state. -
FIG. 2 is an enlarged view of a portion of the stent ofFIG. 1 , at area 2-2. -
FIG. 3 is another enlarged view of a portion of a stent. -
FIG. 4 is an illustration of a stent in a compacted state. -
FIG. 5 is an illustration of a stent in a compacted state. -
FIG. 6 is an illustration of the stent ofFIG. 5 in an expanded state. -
FIG. 7 is a perspective view of a stent. -
FIG. 8 is a perspective view of a stent. -
FIG. 9 is a cross-sectional view of the stent ofFIG. 1 taken along line 9-9. - Referring to
FIG. 1 , an MRI-compatible stent 10 is formed of a composite structure including a plurality ofmetal wires 24 and a plurality of electricallynon-conductive polymer wires 26.Wires ends lumen 20. As shown,metal wires 24 extend spirally in a first direction about thelongitudinal axis 22 of stent 10 (e.g., clockwise as viewed from one end down the longitudinal axis), andpolymer wires 26 extend spirally in an opposing direction (e.g., counter-clockwise as viewed from the same end) about the longitudinal axis. As described below,metal wires 24 providestent 10 with good mechanical properties (e.g., sufficient to maintain a body lumen open), while allowing for visualization of material, such as blood or a stenosis, present in the lumen of the stent during MRI.Polymer wires 26 reduce the amount of metal wires used to formstent 10, thereby increasing the MRI compatibility of the stent, and can enhance the flexibility and strength of the stent. - In preferred embodiments,
metal wires 24 are selected and arranged withinstent 10 such that they do not adversely affect visualization during an MRI procedure, while providing the stent with its mechanical properties to function properly (i.e., the stent can be compacted to a reduced size and subsequently expanded to support a lumen). More specifically,metal wires 24 are formed such that an electrical current cannot flow in a closed loop aboutstent 10. Without wishing to be bound by theory, it is believed that the presence of an electrical current loop can interfere with MRI and reduce visualization. - During MRI, an incident electromagnetic field is applied to a stent. The magnetic environment of the stent can be constant or variable, such as when the stent moves within the magnetic field (e.g., from a beating heart) or when the incident magnetic field is varied. When there is a change in the magnetic environment of the stent, which can act as a coil or a solenoid, an induced electromotive force (emf) is generated, according to Faraday's Law. The induced emf in turn can produce an eddy current that induces a magnetic field that opposes the change in magnetic field. The induced magnetic field can interact with the incident magnetic field to reduce (e.g., distort) the visibility of material in the lumen of the stent. A similar effect can be caused by a radiofrequency pulse applied during MRI.
- By forming
stent 10 to include electrically conductive portions (as shown, wires 24) that cannot form a closed current loop, the occurrence of an eddy current is reduced (e.g., eliminated). Consequently, the occurrence of an induced magnetic field that can interact with the incident magnetic field is also reduced, and the visibility of material in the lumen ofstent 10 during MRI can be enhanced. -
Polymer wires 26 also enhance the performance ofstent 10.Polymer wires 26, which are electrically non-conductive, do not interfere with MRI signals. Also, by formingstent 10 partially withpolymer wires 26, the amount ofmetal wires 24 is reduced, thereby reducing the occurrence of static interference as an effect of the magnetic susceptibility of the metal wires. At the same time,polymer wires 26 can providestent 10 with strength and flexibility. - In some embodiments,
polymer wires 26 are arranged such that they are not substantially plastically deformed during compaction and expansion ofstent 10. Without wishing to be bound by theory, it is believed that asstent 10 is expanded, the majority of change in the stent's width and length, and thus most of the stress, occurs in the radial direction (e.g., perpendicular to longitudinal axis 22). By positioningpolymer wires 26 to have a component alonglongitudinal axis 22, plastic deformation ofpolymer wires 26 can be reduced because the stress experienced by the polymer wires is proportional to their radial component. In certain embodiments, referring toFIGS. 2 and 3 ,polymer wires 26 form an angle of about 45° or less (e.g., ≦45°, 40°, 35°, 30°, 25°, 20°, 15°, 10°, 5°, 0°) with longitudinal axis 22 (e.g., 0°≦α≦45° and thus can be substantially parallel with the longitudinal axis 22). In comparison,metal wires 24 can form an angle of 35° or greater (e.g., ≧35°, 40°, 45°, 50°, 55°, 60°, 65°, 70°, 75°, 80°, 85°, 89°) with the longitudinal axis (e.g., 35°≦β≦90°, e.g., 60°≦β≦85°) and thus can be substantially perpendicular to the longitudinal axis 22). As a result,polymer wires 26 experience reduced stress associated with expansion and contraction and are therefore less likely to undergo plastic deformation. In addition, the stress exerted by a body lumen on an expanded stent is mainly in the radial direction. As a result,metal wires 24 counteract substantially all of the stress exerted by the lumen, thereby reducing the stress experienced bypolymer wires 26. - In some embodiments, the angles that
polymer wires 26 and/ormetal wires 24 form can vary along the length ofstent 10. For example, at the end portions of the stent,polymer wires 26 and/ormetal wires 24 can form a first angle; and at the middle portion of the stent, the polymer wires and/or metal wires can form a second angle. The transitions of one angle to another angle can occur, for example, gradually over the length of the stent or step-wise, such that the stent has discrete segments of different angles form by the wire(s). The angles can be varied to affect the flexibility or rigidity of the stent. For example, the end portions of the stent can be relatively flexible to conform well with the contours of a body vessel, while the middle portion can be relatively rigid to support the vessel open. - Other embodiments of stents having good MRI compatibility are possible. Referring to
FIG. 4 , one of thepolymer wires 26 can be replaced with a metal wire as this design does not lead to closed conductive paths in the stent. In embodiments in which the stent is self expandable (e.g., metal wires include a shape memory material), the self expansion capabilities of the stent can be enhanced because the strength of the stent is increased by including anadditional metal wire 24 that extends spirally in the counter-clockwise direction. - In other embodiments, the MRI visibility capabilities can be enhanced by replacing one or more (e.g., 1, 2, 3, 4, 5, 6, 7, 8 or more) of the
metal wires 24 withpolymer wires 26. The number of metal wires that are replaced with polymer wires depends on the size and shape of the stent, and ultimately on the ability of the remaining metal wires to self expand the stent to an expanded state. It is believed that by reducing the total number of metal wires withinstent 10, magnetic susceptibility disturbances generated by the stent in an MRI decrease, while the contrast to noise ratio increases to provide increased MRI visibility. - In other embodiments, referring to
FIGS. 5 and 6 , the one ormore polymer wires 26 can extend substantially parallel to longitudinal axis 22 (e.g., α=0°) and the one or more metal wires can extend substantially perpendicular to longitudinal axis 22 (e.g., β=90°). - Since polymer wire(s) have a limited (e.g., substantially none) radial component, the polymer wire(s) undergo little plastic deformation during compaction and expansion of the stent. Conversely, metal wire(s) 24 have a large radial component to provide the stent with sufficient mechanical properties to support a body lumen. At least one of the
metal wires 24 can have a sinusoidal shape, so as to provide additional surface contact between an expandedstent 10 and a patient's body lumen. In the embodiments shown inFIGS. 5-8 , one or more polymer wires 26 (e.g., 1, 2, 3, 4, 5, 6, 7, 8 or more) hold themetal wires 24 together. For example, a mechanical connection between thepolymer wires 26 and themetal wires 24 can be created by inserting themetal wires 26 through holes punched into thepolymer wires 26. The mechanical connection can also be created by replacing eachpolymer wire 26 with two polymer wire strips, one in contact with theouter surface 16 and one in contact with theinner surface 18, and fusing the polymer wire strips together to encapsulate a portion of eachmetal wire 26. - As shown in
FIGS. 7 and 8 , eachmetal wire 24 can be formed in a “C” shape (FIG. 7 ) or in a ring shape (FIG. 8 ). Stents, such asstent 10′, which include “C” shaped metal wires (i.e.,metal wires 24 do not create a continuously conductive circuit in a plane perpendicular to longitudinal axis 22) do not interfere with MRI visualization as described above. However,stents 10″ that include ring shaped metal wires, such as the stent shown inFIG. 8 , may interfere with MRI visualization, but may be useful when view or monitored using fluoroscopic techniques. Accordingly, in some embodiments, the rings are formed of a metal (e.g., gold, silver, platinum) visible under fluoroscopy so thatstent 10″ can be visualized within a patient's body during delivery and placement. In certain embodiments,stent 10″ includes one or more metal rings formed of a first material and one or more metal rings formed of a second material. For example, the metal wires labeled 24 a and 24 f inFIG. 8 can be formed of a metal that is more radio-opaque (creates a greater contrast under fluoroscopy) than themetal forming wires wires wires - The stents described above can be self-expanding, balloon expanding, or a combination of both (U.S. Pat. No. 5,366,504), depending on the materials used. For balloon expandable stents, metal wires can include an elastic material that maintains its shape once plastically deformed. Examples of elastic materials include titanium, titanium alloys, tantalum, niobium, Co—Cr alloys, and alloys described in U.S. Ser. No. 10/112,391 filed on Mar. 28, 2002.
- For self expandable stents, metal wires can include a shape memory material that expands and/or contracts as a result of a phase change. Examples of suitable shape memory materials include titanium alloys, such as for example a nickel titanium alloy (e.g., Nitinol), copper aluminum alloys, such as for example Cu—Zn—Al, Cu—Al—Ni, and Cu—Al, Fe—Mn—Si, Au—Ca, and Ni50Mn30Ga20 (Ni50Mn30Ga20 wires prepared from DC magnetron sputtered Ni50Mn30Ga20 films that have been annealed on a glass plate). Typically, elastic and shape memory materials are flexible materials (e.g., modulus of elasticity is less than about 90 GPa) that have sufficient mechanical strength (e.g., ultimate tensile strength greater than 1 GPa) to reinforce a body lumen even after plastic deformation and/or a phase change.
- Metal wires can be molded or laser cut from a solid tube of material to have a spiral shape. The metal wires can have a cross-sectional area of about 2.5×10−5 cm2 to about 2.5×10−3 cm2. In certain embodiments, it is preferable to use a wire that has an oval cross-sectional shape so that the long diameter of the oval can be aligned with (i.e., substantially parallel to) the circumference of
stent 10, as shown inFIG. 9 . By aligning the long diameter with the circumference, the radial expansion force of the stent with respect to the amount of metal material used instent 10 is increased (e.g., maximized). While an oval cross-sectional shape is preferable,metal wires 24 can have other cross-sectional shapes such as, for example, regularly or irregularly polygonal having three or more (e.g., 4, 5, 6, 7, 8 or more) sides, such as rectangular, square, circular, and triangular. Wires of different cross sections can be used in a stent. - Polymer wires used in either self expanding or balloon expanding stents include flexible and strong polymers that have suitable material properties to aid in body lumen reinforcement and at the same time also have material properties that do not compromise the MRI compatibility of the stent. Some examples of polymers include polyethylene, polyimide, polyamide, polycarbonate, polyetheretherketone, and polyethylene terephthalate.
- In certain embodiments,
polymer wires 26 are formed of a highly oriented polymer material, such as polyethylene (e.g., a high density polyethylene (HDPE) material formed using a solid-state extrusion process). The HDPE polymer can have an average molecular weight (Mw) of about 400,000 g/mol, and a molecular weight distribution (i.e., polydispersity) of about 3 to 7, for example, a polydispersity of about 5. The polymer can have a high molecular weight tail (e.g., 0-10% content of greater than about 1,000,000) to ensure the formation of extended chain crystals. A minimal amount (<0.1%) of low molecular weight (e.g., 4000 g/mol or less) fraction is preferred to prevent the premature onset of relaxation processes in the melt and to ensure force transfer during extrusion of the melt through a die. Low molecular weight fractions can be removed by extraction in an appropriate solvent (e.g., hexane) to increase the tensile module of the resulting fiber. Examples of HDPEs are commercially available from, e.g., BASELL (BASF) Corporation under the trade designation LUPULEN 52ZHI; Chevron Philips Corporation under the trade designation MARLEX TR-751; and Solvay Corporation under the trade designations RIGIDEX HM5420 XPH, AH 5493, and BH 5363. - A polymer wire can be prepared, for example, by extrusion. The cross-section of the polymer wire can be as described above for the metal wire. The polymer can be extruded to form relatively stiff fibers having the requisite mechanical properties (e.g., Young's modulus (E) of greater than about 10 GPa and a tensile strength of greater than about 1 GPa). HDPE fibers can be prepared by solid-state extrusion of melt crystallized spherulitic polyethylene or by drawing solution crystallized gel films (e.g., performed by DSM (Heerlen, The Netherlands) as a process marketed as the Dyneema® Process). An alternative process involves melt deformation of HDPE under controlled conditions to obtain highly oriented fibers. The process involves chain extension of the high molecular weight fraction of HDPE having a linear macromolecular structure during flow just above the solidification temperature, followed by crystallization (e.g., of a high molecular weight fraction) and by co-crystallization e.g., of a low molecular weight fraction) of the remaining material. The polymer can be extruded at a temperature close to the crystallization temperature (e.g., a self-blocking temperature, which can be indicated by an extrusion pressure rise, e.g., upward from about 3500 psi) and at a strain rate of about 1000 s−1 to solidify the deformed macromolecules before relaxation occurs. In some cases, crystallization occurs from about Tg+30 to about Tm−10 (e.g., from about 135 to about 160° C.). Such processing conditions can create an elongated, interlocking morphology that displays exceptional mechanical properties (e.g., a Young's modulus (E) of between about 10-80 GPa and a tensile strength of about 1.2 GPa). The fibrils can make up about 5% of the extruded material and can have a diameter of between about 5-25 nm with an aspect ratio of about 200-600. The bulk material can be characterized as a lamellar overgrowth chain direction like in the fibrils. An example of an extrusion apparatus is a mini-extruder (
Axxon BX 12, D=12.5 mm, L/D=26) with a suitably designed die (e.g., opening angle 45°, 1 mm, 1/d 25). The extrusion head can be equipped with a pressure transducer and a thermocouple to control pressure and temperature during extrusion. Additional information regarding HDPEs is described in Bashir, Z., et al., J. Mat. Science, 19 (1984), 3713; and Bashir, Z., et al., J. Mat. Science, 19 (1986), 3993. - In some embodiments, the
polymer wires 26 are extruded to have a preformed spiral shape. In other embodiments, thepolymer wires 26 are molded at a temperature at or below their melting temperature to form the spiral shape. - In some embodiments, the HDPE fibers can be treated with a cold oxygen plasma to increase the biocompatibility of the fibers. Generally, by treating HDPE with a cold oxygen plasma, the hydrophylicity of the surface of the HDPE fibers increases, which results in increased biocompatibility. However, in order to minimize the likelihood of destruction of the interlocking morphology, and thus compromise the mechanical properties of the fibers, the cold oxygen plasma treatment preferably occurs at a temperature at or below the melting temperature of HDPE. An example of a suitable cold oxygen plasma technique with the required low temperature is a downstream microwave plasma technique. As the life expectancy of a plasma treated surface is only limited, it is preferable to provide a coating, such as for example a plastic coating (e.g., styrene-isobutylene-styrene and poly glycerol sebacate), on top of the plasma treated surface.
- In some embodiments, the
polymer wires 26 are formed of a biodegradable polymer material, such as for example, poly (L-lactid acid) that disintegrates over a period of time within the patient's body. Preferably the biodegradable polymer material does not disintegrate until at least a portion of themetal wires 24 are affixed to the patient's body lumen by tissue growth. The biodegradable polymer can include drugs, such as therapeutic agents or pharmaceutically active compounds that are released upon disintegration of the polymer wires. Examples of therapeutic agents and pharmaceutically active compounds include anti-thrombogenic agents, antioxidants, anti-inflammatory agents, anesthetic agents, anti-coagulants, and antibiotics. Other examples suitable therapeutic agents and pharmaceutically active compounds are described in U.S. Pat. No. 5,674,242, commonly assigned U.S. Ser. No. 09/895,415, filed Jul. 2, 2001, and U.S. Ser. No. 10/112,391, filed Mar. 28, 2002. - In other embodiments,
stent 10 can include and/or be attached to a biocompatible, non-porous or semi-porous polymer matrix made of polytetrafluoroethylene (PTFE), expanded PTFE, polyethylene, urethane, or polypropylene. - In some embodiments, the
polymer wires 26 can be coated and/or treated with an anti-coagulant, such as for example heparin, to increase the biocompatibility ofstent - In some embodiments,
stents outer surface 16 and/orinner surface 18 to treat the patient's body lumen. -
Stents stents -
Stents - All of the features disclosed herein may be combined in any combination. Each feature disclosed may be replaced by an alternative feature serving the same, equivalent, or similar purpose. Thus, unless expressly stated otherwise, each feature disclosed is only an example of a generic series of equivalent or similar features.
- All publications, applications, and patents referred to in this application are herein incorporated by reference to the same extent as if each individual publication or patent was specifically and individually indicated to be incorporated by reference in their entirety.
- Other embodiments are within the claims.
Claims (23)
1-26. (canceled)
27. An expandable stent comprising:
a polymer wire extending substantially parallel to a longitudinal axis of the expandable stent; and
a metal wire extending substantially perpendicular to the longitudinal axis, the metal wire contacting the polymer wire.
28. The expandable stent of claim 27 , wherein the metal wire has a sinusoidal shape.
29. The expandable stent of claim 28 , wherein the metal wire is formed in to a C shape.
30. The expandable stent of claim 28 , wherein the metal wire is formed in to a ring.
31. The expandable stent of claim 27 , further comprising a plurality of metal wires extending substantially perpendicular to the longitudinal axis.
32. The expandable stent of claim 31 , wherein the plurality of metal wires include a first metal wire comprising a first metal and a second metal wire comprising a second metal, wherein the first metal differs from the second metal.
33. The expandable stent of claim 27 , wherein the metal wire is visible on a magnetic resonance image.
34. The expandable stent of claim 27 , wherein the polymer wire comprises polyethylene.
35. The expandable stent of claim 34 , wherein the polymer wire comprises high density polyethylene.
36. The expandable stent of claim 35 , wherein the polymer wire is treated with a plasma.
37. The expandable stent of claim 36 , wherein at least a portion of the polymer wire is coated with a plastic.
38. The expandable stent of claim 27 , wherein the polymer wire comprises a biodegradable polymer.
39. The expandable stent of claim 38 , wherein the polymer wire includes a drug within the biodegradable polymer.
40. The expandable stent of claim 27 , further comprising a plurality polymer wires extending substantially parallel to the longitudinal axis.
41. The expandable stent of claim 40 , wherein the plurality of polymer wires includes an inner wire positioned on an inner surface of the expandable stent and an outer wire positioned on an outer surface of the expandable stent.
42. The expandable stent of claim 41 , wherein the inner wire is fused to the outer wire.
43. The expandable stent of claim 40 , wherein the plurality of polymer wires comprises four polymer wires.
44. The expandable stent of claim 40 , wherein the plurality of polymer wires comprises six polymer wires.
45. The expandable stent of claim 40 , wherein the plurality of polymer wires comprises eight polymer wires.
46. The expandable stent of claim 27 , wherein the polymer wire includes an aperture and the metal wire is positioned within the aperture.
47. The expandable stent of claim 27 , wherein the expandable stent is balloon expandable.
48-75. (canceled)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/631,430 US20100082093A1 (en) | 2004-01-22 | 2009-12-04 | Medical Devices |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/762,815 US7632299B2 (en) | 2004-01-22 | 2004-01-22 | Medical devices |
US12/631,430 US20100082093A1 (en) | 2004-01-22 | 2009-12-04 | Medical Devices |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/762,815 Continuation US7632299B2 (en) | 2004-01-22 | 2004-01-22 | Medical devices |
Publications (1)
Publication Number | Publication Date |
---|---|
US20100082093A1 true US20100082093A1 (en) | 2010-04-01 |
Family
ID=34794935
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/762,815 Expired - Fee Related US7632299B2 (en) | 2004-01-22 | 2004-01-22 | Medical devices |
US12/631,430 Abandoned US20100082093A1 (en) | 2004-01-22 | 2009-12-04 | Medical Devices |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/762,815 Expired - Fee Related US7632299B2 (en) | 2004-01-22 | 2004-01-22 | Medical devices |
Country Status (5)
Country | Link |
---|---|
US (2) | US7632299B2 (en) |
EP (1) | EP1706067A1 (en) |
JP (1) | JP2007518520A (en) |
CA (1) | CA2552992A1 (en) |
WO (1) | WO2005072653A1 (en) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104042297A (en) * | 2013-03-13 | 2014-09-17 | 德普伊新特斯产品有限责任公司 | Braided flow diverter using flat-round technology |
US20140277573A1 (en) * | 2013-03-15 | 2014-09-18 | Merit Medical Systems, Inc. | Esophageal stent |
KR101668373B1 (en) * | 2015-06-09 | 2016-10-21 | 전북대학교산학협력단 | Re-expansible stent and treatment apparatus using it |
US9474638B2 (en) | 2013-03-05 | 2016-10-25 | Merit Medical Systems, Inc. | Reinforced valve |
US9687367B2 (en) | 2012-06-05 | 2017-06-27 | Merit Medical Systems, Inc. | Esophageal stent |
US9713522B2 (en) | 2011-10-31 | 2017-07-25 | Merit Medical Systems, Inc. | Esophageal stent with valve |
WO2018001133A1 (en) * | 2016-06-28 | 2018-01-04 | 微创心脉医疗科技(上海)有限公司 | Membrane-coated stent and manufacturing method thereof |
CN108236512A (en) * | 2016-12-27 | 2018-07-03 | 先健科技(深圳)有限公司 | Overlay film frame |
US10285798B2 (en) | 2011-06-03 | 2019-05-14 | Merit Medical Systems, Inc. | Esophageal stent |
CN109966020A (en) * | 2017-12-27 | 2019-07-05 | 先健科技(深圳)有限公司 | Overlay film frame |
CN110461382A (en) * | 2017-01-25 | 2019-11-15 | B.布劳恩梅尔松根股份公司 | Intracavitary unit |
US10966848B2 (en) | 2016-12-29 | 2021-04-06 | Boston Scientific Scimed, Inc. | Medical devices formed from polymer filaments |
US11096774B2 (en) | 2016-12-09 | 2021-08-24 | Zenflow, Inc. | Systems, devices, and methods for the accurate deployment of an implant in the prostatic urethra |
US11890213B2 (en) | 2019-11-19 | 2024-02-06 | Zenflow, Inc. | Systems, devices, and methods for the accurate deployment and imaging of an implant in the prostatic urethra |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8382821B2 (en) * | 1998-12-03 | 2013-02-26 | Medinol Ltd. | Helical hybrid stent |
US20070219642A1 (en) * | 1998-12-03 | 2007-09-20 | Jacob Richter | Hybrid stent having a fiber or wire backbone |
AU2002345328A1 (en) | 2001-06-27 | 2003-03-03 | Remon Medical Technologies Ltd. | Method and device for electrochemical formation of therapeutic species in vivo |
DE102012016301B3 (en) * | 2012-08-16 | 2013-12-12 | Admedes Schuessler Gmbh | Method for producing a body implant |
US9155639B2 (en) | 2009-04-22 | 2015-10-13 | Medinol Ltd. | Helical hybrid stent |
US9039755B2 (en) | 2003-06-27 | 2015-05-26 | Medinol Ltd. | Helical hybrid stent |
US20050278017A1 (en) * | 2004-06-09 | 2005-12-15 | Scimed Life Systems, Inc. | Overlapped stents for scaffolding, flexibility and MRI compatibility |
US8066759B2 (en) | 2005-02-04 | 2011-11-29 | Boston Scientific Scimed, Inc. | Resonator for medical device |
JP4824747B2 (en) * | 2005-03-24 | 2011-11-30 | メドトロニック カルディオ ヴァスキュラー インコーポレイテッド | Intravascular stent and intravascular stent delivery system |
US7595469B2 (en) * | 2005-05-24 | 2009-09-29 | Boston Scientific Scimed, Inc. | Resonator for medical device |
US7279664B2 (en) | 2005-07-26 | 2007-10-09 | Boston Scientific Scimed, Inc. | Resonator for medical device |
US7304277B2 (en) | 2005-08-23 | 2007-12-04 | Boston Scientific Scimed, Inc | Resonator with adjustable capacitor for medical device |
US7524282B2 (en) | 2005-08-29 | 2009-04-28 | Boston Scientific Scimed, Inc. | Cardiac sleeve apparatus, system and method of use |
US7423496B2 (en) | 2005-11-09 | 2008-09-09 | Boston Scientific Scimed, Inc. | Resonator with adjustable capacitance for medical device |
US8840660B2 (en) | 2006-01-05 | 2014-09-23 | Boston Scientific Scimed, Inc. | Bioerodible endoprostheses and methods of making the same |
US8089029B2 (en) | 2006-02-01 | 2012-01-03 | Boston Scientific Scimed, Inc. | Bioabsorbable metal medical device and method of manufacture |
US9615832B2 (en) * | 2006-04-07 | 2017-04-11 | Penumbra, Inc. | Aneurysm occlusion system and method |
US8048150B2 (en) | 2006-04-12 | 2011-11-01 | Boston Scientific Scimed, Inc. | Endoprosthesis having a fiber meshwork disposed thereon |
US8052743B2 (en) | 2006-08-02 | 2011-11-08 | Boston Scientific Scimed, Inc. | Endoprosthesis with three-dimensional disintegration control |
US20080039926A1 (en) * | 2006-08-11 | 2008-02-14 | Majercak David C | Stent graft sealing zone connecting structure |
WO2008030488A2 (en) * | 2006-09-06 | 2008-03-13 | Med Institute, Inc. | Stents with connectors and stabilizing biodegradable elements |
EP2959925B1 (en) | 2006-09-15 | 2018-08-29 | Boston Scientific Limited | Medical devices and methods of making the same |
JP2010503494A (en) | 2006-09-15 | 2010-02-04 | ボストン サイエンティフィック リミテッド | Biodegradable endoprosthesis and method for producing the same |
JP2010503490A (en) | 2006-09-15 | 2010-02-04 | ボストン サイエンティフィック リミテッド | Endoprosthesis with adjustable surface features |
EP2210625B8 (en) | 2006-09-15 | 2012-02-29 | Boston Scientific Scimed, Inc. | Bioerodible endoprosthesis with biostable inorganic layers |
CA2663250A1 (en) | 2006-09-15 | 2008-03-20 | Boston Scientific Limited | Bioerodible endoprostheses and methods of making the same |
CA2663762A1 (en) | 2006-09-18 | 2008-03-27 | Boston Scientific Limited | Endoprostheses |
ES2382364T3 (en) * | 2006-09-28 | 2012-06-07 | St George Medical Inc | Thoracic aortic aneurysm repair device. |
EP2076212B1 (en) * | 2006-10-18 | 2017-03-29 | Inspiremd Ltd. | Knitted stent jackets |
ES2506144T3 (en) | 2006-12-28 | 2014-10-13 | Boston Scientific Limited | Bioerodible endoprosthesis and their manufacturing procedure |
US9387100B2 (en) * | 2007-01-08 | 2016-07-12 | Cardinal Health Switzerland GmbH | Intraluminal medical device having variable axial flexibility about the circumference of the device |
US9265636B2 (en) * | 2007-05-25 | 2016-02-23 | C. R. Bard, Inc. | Twisted stent |
US8052745B2 (en) | 2007-09-13 | 2011-11-08 | Boston Scientific Scimed, Inc. | Endoprosthesis |
EP2186492B1 (en) * | 2007-09-27 | 2012-08-15 | Terumo Kabushiki Kaisha | Stent and living organ dilator |
CN101515028B (en) * | 2008-02-19 | 2012-05-30 | 西门子公司 | Three-dimensional imaging method and system for alleviating magnetic susceptibility artifact |
US8221494B2 (en) | 2008-02-22 | 2012-07-17 | Endologix, Inc. | Apparatus and method of placement of a graft or graft system |
US7998192B2 (en) | 2008-05-09 | 2011-08-16 | Boston Scientific Scimed, Inc. | Endoprostheses |
US8236046B2 (en) | 2008-06-10 | 2012-08-07 | Boston Scientific Scimed, Inc. | Bioerodible endoprosthesis |
EP2520320B1 (en) | 2008-07-01 | 2016-11-02 | Endologix, Inc. | Catheter system |
US7985252B2 (en) | 2008-07-30 | 2011-07-26 | Boston Scientific Scimed, Inc. | Bioerodible endoprosthesis |
US8382824B2 (en) | 2008-10-03 | 2013-02-26 | Boston Scientific Scimed, Inc. | Medical implant having NANO-crystal grains with barrier layers of metal nitrides or fluorides |
US8267992B2 (en) | 2009-03-02 | 2012-09-18 | Boston Scientific Scimed, Inc. | Self-buffering medical implants |
US20110054586A1 (en) | 2009-04-28 | 2011-03-03 | Endologix, Inc. | Apparatus and method of placement of a graft or graft system |
US8668732B2 (en) | 2010-03-23 | 2014-03-11 | Boston Scientific Scimed, Inc. | Surface treated bioerodible metal endoprostheses |
US20120109279A1 (en) | 2010-11-02 | 2012-05-03 | Endologix, Inc. | Apparatus and method of placement of a graft or graft system |
EP2680915B1 (en) | 2011-03-01 | 2021-12-22 | Endologix LLC | Catheter system |
JP5751619B2 (en) | 2011-04-14 | 2015-07-22 | 朝日インテック株式会社 | Stent |
CA2874727A1 (en) * | 2012-06-04 | 2013-12-12 | Penumbra, Inc. | Aneurysm occlusion system and method |
FR2993451A1 (en) * | 2012-07-17 | 2014-01-24 | St George Medical Inc | ENDOLUMINAL VASCULAR PROSTHESIS FOR SMALL VESSELS |
FR2995523A1 (en) * | 2012-09-18 | 2014-03-21 | Ct Hospitalier Universitaire Rouen | ENDO-URETHRAL PROSTHESIS |
CN103417317A (en) * | 2013-08-16 | 2013-12-04 | 江苏大学 | Intravascular stent |
KR101650514B1 (en) * | 2014-06-19 | 2016-08-23 | 주식회사 엠아이텍 | Hybrid Vascular Stent |
EP3139860B1 (en) | 2015-06-30 | 2024-06-12 | Endologix LLC | Locking assembly for coupling guidewire to delivery system |
KR101721485B1 (en) * | 2015-09-04 | 2017-03-31 | 연세대학교 산학협력단 | A stent for medical |
US11191655B2 (en) * | 2018-11-04 | 2021-12-07 | Biosert Ltd. | Expanding stent |
FR3093913B1 (en) * | 2019-03-18 | 2023-10-20 | Mdb Texinov | Vascular stent |
CN111557771B (en) * | 2020-07-15 | 2020-11-24 | 首都医科大学附属北京世纪坛医院 | Partially bioabsorbable stent and preparation method thereof |
CN111938886B (en) * | 2020-08-21 | 2022-09-20 | 深圳市人民医院 | Balloon expanding type support and taking-out device thereof |
Citations (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4655771A (en) * | 1982-04-30 | 1987-04-07 | Shepherd Patents S.A. | Prosthesis comprising an expansible or contractile tubular body |
US5163952A (en) * | 1990-09-14 | 1992-11-17 | Michael Froix | Expandable polymeric stent with memory and delivery apparatus and method |
US5195969A (en) * | 1991-04-26 | 1993-03-23 | Boston Scientific Corporation | Co-extruded medical balloons and catheter using such balloons |
US5258020A (en) * | 1990-09-14 | 1993-11-02 | Michael Froix | Method of using expandable polymeric stent with memory |
US5270086A (en) * | 1989-09-25 | 1993-12-14 | Schneider (Usa) Inc. | Multilayer extrusion of angioplasty balloons |
US5332402A (en) * | 1992-05-12 | 1994-07-26 | Teitelbaum George P | Percutaneously-inserted cardiac valve |
US5366504A (en) * | 1992-05-20 | 1994-11-22 | Boston Scientific Corporation | Tubular medical prosthesis |
US5591223A (en) * | 1992-11-23 | 1997-01-07 | Children's Medical Center Corporation | Re-expandable endoprosthesis |
US5607442A (en) * | 1995-11-13 | 1997-03-04 | Isostent, Inc. | Stent with improved radiopacity and appearance characteristics |
US5643312A (en) * | 1994-02-25 | 1997-07-01 | Fischell Robert | Stent having a multiplicity of closed circular structures |
US5665114A (en) * | 1994-08-12 | 1997-09-09 | Meadox Medicals, Inc. | Tubular expanded polytetrafluoroethylene implantable prostheses |
US5674242A (en) * | 1995-06-06 | 1997-10-07 | Quanam Medical Corporation | Endoprosthetic device with therapeutic compound |
US5843158A (en) * | 1996-01-05 | 1998-12-01 | Medtronic, Inc. | Limited expansion endoluminal prostheses and methods for their use |
US5954744A (en) * | 1995-06-06 | 1999-09-21 | Quanam Medical Corporation | Intravascular stent |
US6113567A (en) * | 1995-10-25 | 2000-09-05 | Becker; Bruce B. | Lacrimal silicone tube with reduced friction |
US6168619B1 (en) * | 1998-10-16 | 2001-01-02 | Quanam Medical Corporation | Intravascular stent having a coaxial polymer member and end sleeves |
US6248129B1 (en) * | 1990-09-14 | 2001-06-19 | Quanam Medical Corporation | Expandable polymeric stent with memory and delivery apparatus and method |
US6340367B1 (en) * | 1997-08-01 | 2002-01-22 | Boston Scientific Scimed, Inc. | Radiopaque markers and methods of using the same |
US20020128706A1 (en) * | 2001-02-06 | 2002-09-12 | Peter Osypka | Implantable stent |
US6471721B1 (en) * | 1999-12-30 | 2002-10-29 | Advanced Cardiovascular Systems, Inc. | Vascular stent having increased radiopacity and method for making same |
US20020188345A1 (en) * | 2001-06-06 | 2002-12-12 | Pacetti Stephen Dirk | MRI compatible stent |
US20030004563A1 (en) * | 2001-06-29 | 2003-01-02 | Jackson Gregg A. | Polymeric stent suitable for imaging by MRI and fluoroscopy |
US20030018380A1 (en) * | 2000-07-07 | 2003-01-23 | Craig Charles H. | Platinum enhanced alloy and intravascular or implantable medical devices manufactured therefrom |
US6530950B1 (en) * | 1999-01-12 | 2003-03-11 | Quanam Medical Corporation | Intraluminal stent having coaxial polymer member |
US6565599B1 (en) * | 2000-12-28 | 2003-05-20 | Advanced Cardiovascular Systems, Inc. | Hybrid stent |
US6585758B1 (en) * | 1999-11-16 | 2003-07-01 | Scimed Life Systems, Inc. | Multi-section filamentary endoluminal stent |
US20030135265A1 (en) * | 2002-01-04 | 2003-07-17 | Stinson Jonathan S. | Prostheses implantable in enteral vessels |
US20030212449A1 (en) * | 2001-12-28 | 2003-11-13 | Cox Daniel L. | Hybrid stent |
US6676987B2 (en) * | 2001-07-02 | 2004-01-13 | Scimed Life Systems, Inc. | Coating a medical appliance with a bubble jet printing head |
US20040093077A1 (en) * | 2002-08-06 | 2004-05-13 | Jason White | Stent with micro-latching hinge joints |
US20040093076A1 (en) * | 2002-08-06 | 2004-05-13 | Jason White | Helical stent with micro-latches |
US20060036311A1 (en) * | 2002-08-23 | 2006-02-16 | Yasuhide Nakayama | Stent and process for producing the same |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1258229A1 (en) | 2001-05-15 | 2002-11-20 | Vascular Technologies, Inc. | Flexible and elastic vascular stents and grafts |
CN111886190B (en) | 2018-03-22 | 2022-06-28 | 村田机械株式会社 | Stocker system |
-
2004
- 2004-01-22 US US10/762,815 patent/US7632299B2/en not_active Expired - Fee Related
-
2005
- 2005-01-06 JP JP2006551110A patent/JP2007518520A/en active Pending
- 2005-01-06 EP EP05705102A patent/EP1706067A1/en not_active Withdrawn
- 2005-01-06 CA CA002552992A patent/CA2552992A1/en not_active Abandoned
- 2005-01-06 WO PCT/US2005/000314 patent/WO2005072653A1/en not_active Application Discontinuation
-
2009
- 2009-12-04 US US12/631,430 patent/US20100082093A1/en not_active Abandoned
Patent Citations (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4655771A (en) * | 1982-04-30 | 1987-04-07 | Shepherd Patents S.A. | Prosthesis comprising an expansible or contractile tubular body |
US4655771B1 (en) * | 1982-04-30 | 1996-09-10 | Medinvent Ams Sa | Prosthesis comprising an expansible or contractile tubular body |
US5270086A (en) * | 1989-09-25 | 1993-12-14 | Schneider (Usa) Inc. | Multilayer extrusion of angioplasty balloons |
US6248129B1 (en) * | 1990-09-14 | 2001-06-19 | Quanam Medical Corporation | Expandable polymeric stent with memory and delivery apparatus and method |
US5258020A (en) * | 1990-09-14 | 1993-11-02 | Michael Froix | Method of using expandable polymeric stent with memory |
US5607467A (en) * | 1990-09-14 | 1997-03-04 | Froix; Michael | Expandable polymeric stent with memory and delivery apparatus and method |
US5163952A (en) * | 1990-09-14 | 1992-11-17 | Michael Froix | Expandable polymeric stent with memory and delivery apparatus and method |
US5195969A (en) * | 1991-04-26 | 1993-03-23 | Boston Scientific Corporation | Co-extruded medical balloons and catheter using such balloons |
US5332402A (en) * | 1992-05-12 | 1994-07-26 | Teitelbaum George P | Percutaneously-inserted cardiac valve |
US5366504A (en) * | 1992-05-20 | 1994-11-22 | Boston Scientific Corporation | Tubular medical prosthesis |
US5591223A (en) * | 1992-11-23 | 1997-01-07 | Children's Medical Center Corporation | Re-expandable endoprosthesis |
US5643312A (en) * | 1994-02-25 | 1997-07-01 | Fischell Robert | Stent having a multiplicity of closed circular structures |
US5665114A (en) * | 1994-08-12 | 1997-09-09 | Meadox Medicals, Inc. | Tubular expanded polytetrafluoroethylene implantable prostheses |
US5674242A (en) * | 1995-06-06 | 1997-10-07 | Quanam Medical Corporation | Endoprosthetic device with therapeutic compound |
US5954744A (en) * | 1995-06-06 | 1999-09-21 | Quanam Medical Corporation | Intravascular stent |
US6113567A (en) * | 1995-10-25 | 2000-09-05 | Becker; Bruce B. | Lacrimal silicone tube with reduced friction |
US5607442A (en) * | 1995-11-13 | 1997-03-04 | Isostent, Inc. | Stent with improved radiopacity and appearance characteristics |
US5843158A (en) * | 1996-01-05 | 1998-12-01 | Medtronic, Inc. | Limited expansion endoluminal prostheses and methods for their use |
US6340367B1 (en) * | 1997-08-01 | 2002-01-22 | Boston Scientific Scimed, Inc. | Radiopaque markers and methods of using the same |
US6168619B1 (en) * | 1998-10-16 | 2001-01-02 | Quanam Medical Corporation | Intravascular stent having a coaxial polymer member and end sleeves |
US6653426B2 (en) * | 1999-01-12 | 2003-11-25 | Quanam Medical Corporation | Polymer compositions for intraluminal stent |
US6530950B1 (en) * | 1999-01-12 | 2003-03-11 | Quanam Medical Corporation | Intraluminal stent having coaxial polymer member |
US6585758B1 (en) * | 1999-11-16 | 2003-07-01 | Scimed Life Systems, Inc. | Multi-section filamentary endoluminal stent |
US6471721B1 (en) * | 1999-12-30 | 2002-10-29 | Advanced Cardiovascular Systems, Inc. | Vascular stent having increased radiopacity and method for making same |
US20030018380A1 (en) * | 2000-07-07 | 2003-01-23 | Craig Charles H. | Platinum enhanced alloy and intravascular or implantable medical devices manufactured therefrom |
US6565599B1 (en) * | 2000-12-28 | 2003-05-20 | Advanced Cardiovascular Systems, Inc. | Hybrid stent |
US6770089B1 (en) * | 2000-12-28 | 2004-08-03 | Advanced Cardiovascular Systems, Inc. | Hybrid stent fabrication using metal rings and polymeric links |
US6964677B2 (en) * | 2001-02-06 | 2005-11-15 | Peter Osypka | Implantable stent |
US20020128706A1 (en) * | 2001-02-06 | 2002-09-12 | Peter Osypka | Implantable stent |
US20020188345A1 (en) * | 2001-06-06 | 2002-12-12 | Pacetti Stephen Dirk | MRI compatible stent |
US6585755B2 (en) * | 2001-06-29 | 2003-07-01 | Advanced Cardiovascular | Polymeric stent suitable for imaging by MRI and fluoroscopy |
US20030004563A1 (en) * | 2001-06-29 | 2003-01-02 | Jackson Gregg A. | Polymeric stent suitable for imaging by MRI and fluoroscopy |
US6676987B2 (en) * | 2001-07-02 | 2004-01-13 | Scimed Life Systems, Inc. | Coating a medical appliance with a bubble jet printing head |
US20030212449A1 (en) * | 2001-12-28 | 2003-11-13 | Cox Daniel L. | Hybrid stent |
US20030135265A1 (en) * | 2002-01-04 | 2003-07-17 | Stinson Jonathan S. | Prostheses implantable in enteral vessels |
US20040093076A1 (en) * | 2002-08-06 | 2004-05-13 | Jason White | Helical stent with micro-latches |
US20040093077A1 (en) * | 2002-08-06 | 2004-05-13 | Jason White | Stent with micro-latching hinge joints |
US20060036311A1 (en) * | 2002-08-23 | 2006-02-16 | Yasuhide Nakayama | Stent and process for producing the same |
Cited By (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10285798B2 (en) | 2011-06-03 | 2019-05-14 | Merit Medical Systems, Inc. | Esophageal stent |
US9713522B2 (en) | 2011-10-31 | 2017-07-25 | Merit Medical Systems, Inc. | Esophageal stent with valve |
US9687367B2 (en) | 2012-06-05 | 2017-06-27 | Merit Medical Systems, Inc. | Esophageal stent |
US9474638B2 (en) | 2013-03-05 | 2016-10-25 | Merit Medical Systems, Inc. | Reinforced valve |
KR102213982B1 (en) | 2013-03-13 | 2021-02-09 | 디퍼이 신테스 프로덕츠, 인코포레이티드 | Braided flow diverter using flat-round technology |
US20150297374A1 (en) * | 2013-03-13 | 2015-10-22 | DePuy Synthes Products, Inc. | Braided flow diverter using flat-round technology |
KR20140112403A (en) * | 2013-03-13 | 2014-09-23 | 디퍼이 신테스 프로덕츠, 엘엘씨 | Braided flow diverter using flat-round technology |
US11389311B2 (en) * | 2013-03-13 | 2022-07-19 | DePuy Synthes Products, Inc. | Braided flow diverter using flat-round technology |
CN104042297A (en) * | 2013-03-13 | 2014-09-17 | 德普伊新特斯产品有限责任公司 | Braided flow diverter using flat-round technology |
AU2018226374B2 (en) * | 2013-03-13 | 2020-01-23 | DePuy Synthes Products, LLC | Braided flow diverter using flat-round technology |
US10588762B2 (en) * | 2013-03-15 | 2020-03-17 | Merit Medical Systems, Inc. | Esophageal stent |
CN104936557A (en) * | 2013-03-15 | 2015-09-23 | 美国医疗设备有限公司 | Esophageal stent |
US20140277573A1 (en) * | 2013-03-15 | 2014-09-18 | Merit Medical Systems, Inc. | Esophageal stent |
WO2016200103A1 (en) * | 2015-06-09 | 2016-12-15 | 전북대학교산학협력단 | Re-expandable stent, and treatment apparatus using same |
KR101668373B1 (en) * | 2015-06-09 | 2016-10-21 | 전북대학교산학협력단 | Re-expansible stent and treatment apparatus using it |
WO2018001133A1 (en) * | 2016-06-28 | 2018-01-04 | 微创心脉医疗科技(上海)有限公司 | Membrane-coated stent and manufacturing method thereof |
CN107536658A (en) * | 2016-06-28 | 2018-01-05 | 微创心脉医疗科技(上海)有限公司 | Overlay film frame and its manufacture method |
US11096774B2 (en) | 2016-12-09 | 2021-08-24 | Zenflow, Inc. | Systems, devices, and methods for the accurate deployment of an implant in the prostatic urethra |
US11903859B1 (en) | 2016-12-09 | 2024-02-20 | Zenflow, Inc. | Methods for deployment of an implant |
US11998438B2 (en) | 2016-12-09 | 2024-06-04 | Zenflow, Inc. | Systems, devices, and methods for the accurate deployment of an implant in the prostatic urethra |
US12090040B2 (en) | 2016-12-09 | 2024-09-17 | Zenflow, Inc. | Methods for deployment of an implant |
CN108236512A (en) * | 2016-12-27 | 2018-07-03 | 先健科技(深圳)有限公司 | Overlay film frame |
US10966848B2 (en) | 2016-12-29 | 2021-04-06 | Boston Scientific Scimed, Inc. | Medical devices formed from polymer filaments |
CN110461382A (en) * | 2017-01-25 | 2019-11-15 | B.布劳恩梅尔松根股份公司 | Intracavitary unit |
US11324862B2 (en) | 2017-01-25 | 2022-05-10 | B. Braun Melsungen Ag | Endoluminal device |
CN109966020A (en) * | 2017-12-27 | 2019-07-05 | 先健科技(深圳)有限公司 | Overlay film frame |
US11890213B2 (en) | 2019-11-19 | 2024-02-06 | Zenflow, Inc. | Systems, devices, and methods for the accurate deployment and imaging of an implant in the prostatic urethra |
Also Published As
Publication number | Publication date |
---|---|
EP1706067A1 (en) | 2006-10-04 |
CA2552992A1 (en) | 2005-08-11 |
JP2007518520A (en) | 2007-07-12 |
US7632299B2 (en) | 2009-12-15 |
US20050165470A1 (en) | 2005-07-28 |
WO2005072653A1 (en) | 2005-08-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7632299B2 (en) | Medical devices | |
US9649210B2 (en) | Hybrid stent and method of making | |
US9833310B2 (en) | Medical devices including metallic film and at least one filament | |
US7854760B2 (en) | Medical devices including metallic films | |
EP1229862B1 (en) | Encapsulated stent preform | |
US20060276910A1 (en) | Endoprostheses | |
US8435280B2 (en) | Flexible stent with variable width elements | |
US20110054589A1 (en) | Stent with variable cross section braiding filament and method for making same | |
US20120035714A1 (en) | Stent Graft Having A Marker And A Reinforcing And Marker Ring | |
US20060129233A1 (en) | Expandable coil stent | |
US20140144001A1 (en) | Stent having function elements | |
US10213290B2 (en) | Braided stent and method of manufacturing a braided stent | |
US20230157852A1 (en) | Bio-alloy braided self-expanding biodegradable stent | |
JP2005342105A (en) | Stent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: SCIMED LIFE SYSTEMS, INC.,MINNESOTA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:WEBER, JAN;REEL/FRAME:023735/0126 Effective date: 20040116 |
|
AS | Assignment |
Owner name: BOSTON SCIENTIFIC SCIMED, INC.,MINNESOTA Free format text: CHANGE OF NAME;ASSIGNOR:SCIMED LIFE SYSTEMS, INC.;REEL/FRAME:023872/0948 Effective date: 20041222 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |